Mersana Therapeutics在1月5日更新了XMT-1536(UpRi)的临床数据。XMT-1536是靶向NaPi2b的抗体偶联药物(ADC),在1期临床的卵巢癌拓展队列中,ORR数据从去年5月公布的35%下降至28%,安全性上有31%的患者由于治疗引起的不良反应减少剂量、推迟用药或停止治疗,39%的患者发生严重不良事件,发生了1例5级肺炎。截止1月5日...
Introduction/Background UpRi is a first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous epithelial ovarian, ...
· 英文名称 Upifitamab Rilsodotin(UpRi)/XMT-1536 · 结构 · 简介 Upifitamab Rilsodotin(XMT-1536)是一种新型抗体-药物偶联物(ADC),由靶向NaPi2b的IgG抗体与细胞毒性药物AF-HPA通过创新型连接子偶联而成。XMT-1536能够实现肿瘤表面药物浓度的显著提升,同时其有效载荷AF-HPA具备可控的旁观者效应和有限的扩...
Upifitamab rilsodotin (UpRi) is a Dolaflexin, high Drug-to-Antibody Ratio ADC targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in high-grade serous epithelial ovarian cancer, with limited expression in normal tissues. UPLIFT was a single-arm Ph2 trial evaluating the ...
UpRi activity was observed in pts previously failing platinum, bevacizumab, and PARP inhibitors. These data support further clinical development of UpRi in a single-arm registrational strategy utilizing 36mg/m2up to a max dose of approximately 80mg every four weeks (UPLIFT; NCT03319628)....
Objectives UpRi is a first-in-class NaPi2b ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous ovarian cancer (HGSOC), with limited ...